Your browser doesn't support javascript.
loading
Neutralizing SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Give Patients with X-Linked Agammaglobulinemia Limited Passive Immunity to the Omicron Variant.
Lindahl, Hannes; Klingström, Jonas; Da Silva Rodrigues, Rui; Christ, Wanda; Chen, Puran; Ljunggren, Hans-Gustaf; Buggert, Marcus; Aleman, Soo; Smith, C I Edvard; Bergman, Peter.
Affiliation
  • Lindahl H; Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Klingström J; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Da Silva Rodrigues R; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Christ W; Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Chen P; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Ljunggren HG; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Buggert M; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Aleman S; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Smith CIE; Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
  • Bergman P; Department of Infectious Diseases, Karolinska University Hospital, Stockholm, Sweden.
J Clin Immunol ; 42(6): 1130-1136, 2022 08.
Article in En | MEDLINE | ID: mdl-35538387

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: En Journal: J Clin Immunol Year: 2022 Document type: Article Affiliation country: Suecia

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: En Journal: J Clin Immunol Year: 2022 Document type: Article Affiliation country: Suecia